Annovis Bio Inc

The Alzheimer's disease market across the seven major markets was valued at approximately USD 4 billion in 2025 and is projected to expand at a CAGR of 22.7% through 2036, according to DelveInsight. The growth is driven by increasing disease prevalence, broader adoption of disease-modifying therapies, advancements in biomarker-based diagnosis, and a robust late-stage pipeline. Key emerging therapies include Masupirdine from Suven Life Sciences, Roche's Trontinemab, Annovis Bio's Buntanetap, AB Science's Masitinib, Eli Lilly's Remternetug, Axsome Therapeutics' AUVELITY, Biovie's Bezisterim, ALZHEON's Valiltramiprosate, TauRx Therapeutics' Hydromethylthionine mesylate, Bristol Myers Squibb's COBENFY, AriBio's AR1001, Acadia Pharmaceuticals' Remlifanserin, and Cerecin's Tricaprilin. The report highlights six late-stage candidates poised to enter the market, including Masupirdine, Trontinemab, AXS-05, COBENFY, Remternetug, and Buntanetap, each with distinct mechanisms of action and anticipated clinical milestones.

The Parkinson's disease clinical trial pipeline has expanded significantly, with more than 150 companies now developing over 200 pipeline drugs, according to a new report from DelveInsight. Key companies such as NeuroDerm, Annovis Bio, Cerevance, Alto Neuroscience, Biogen, Denali Therapeutics, and Arrowhead Pharmaceuticals are evaluating new therapies, with approximately 11-plus drugs in late-stage development. Promising pipeline therapies include ND0612, Buntanetap, CVN424, ALTO-208, Pirepemat, ACD-856, DNL151, and NouvNeu001, among others, targeting mechanisms like alpha-synuclein inhibitors, GPR6 protein inhibitors, and dopamine receptor agonists. Recent milestones include Biogen and Denali Therapeutics reporting Phase IIb results for BIIB122 in May 2026, Cerevance completing enrollment in a pivotal Phase III trial for solengepras, and iRegene Therapeutics receiving RMAT designation for NouvNeu001 in January 2026. The report highlights a robust competitive landscape and ongoing advances in disease-modifying approaches for Parkinson's disease.

Annovis Bio has promoted Cheng Fang to Chief Scientific Officer. Dr. Fang joined the company in 2021 and most recently served as Senior Vice President of Research and Development. She will now lead scientific strategy and research operations across the company's Alzheimer's and Parkinson's disease programs, including translational science, clinical development, biomarker strategy, and regulatory interactions. Her promotion comes as Annovis advances its lead drug candidate, buntanetap, toward top-line data readout from a pivotal Phase 3 Alzheimer's study and a subsequent New Drug Application submission.